Form 4: Rocket Pharmaceuticals CFO Sells Shares for Tax Obligations

Rocket Pharmaceuticals' Chief Financial Officer, Aaron Ondrey, sold 1,477 shares of common stock on July 3, 2025, at $2.882 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Aaron Ondrey, Chief Financial Officer of Rocket Pharmaceuticals, Inc. (RCKT), reported a transaction on July 3, 2025.
• The transaction involved the sale of 1,477 shares of common stock.
• The shares were sold at a price of $2.882 per share.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Aaron Ondrey beneficially owns 128,173 shares of common stock, which includes RSUs that convert to common stock on a one-for-one basis.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares to cover tax obligations related to RSU vesting, which is a common practice and does not indicate a change in company fundamentals or management's view of the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Industry Context

This transaction is a routine insider filing common across all industries for executives receiving equity compensation, specifically Restricted Stock Units (RSUs). It reflects a standard practice for managing tax liabilities upon the vesting of such awards.

Comparison to Industry Standards

• The sale of shares by an executive to cover tax withholding obligations upon the vesting of equity awards like RSUs is a standard and widely accepted practice across all industries and company sizes. It is a common mechanism for executives to manage the tax implications of their compensation without necessarily indicating a change in their long-term view of the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related sale of a relatively small number of shares by an executive, not indicative of a change in company fundamentals or management's confidence.

Key Dates

Recommendation

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Aaron Ondrey, Chief Financial Officer